Euclid Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Euclid Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-63,647	Closed	-$4.68M	–	82
2016 Q2	$4.68M	Buy	63,647 +31,530	+98%	+$2.23M	0.2%	172
2016 Q1	$2.05M	Sell	32,117 -56,514	-64%	-$3.56M	0.08%	276
2015 Q4	$6.1M	Buy	+88,631	New	+$5.86M	0.19%	166
2015 Q3	–	Sell	-132,950	Closed	-$8.85M	–	252
2015 Q2	$8.85M	Sell	132,950 -475,030	-78%	-$31.3M	0.17%	187
2015 Q1	$39.2M	Buy	+607,980	New	+$38.1M	0.72%	28
2014 Q4	–	Sell	-847,460	Closed	-$43.4M	–	385
2014 Q3	$43.4M	Buy	847,460 +53,240	+7%	+$2.66M	0.31%	69
2014 Q2	$38.5M	Sell	794,220 -117,817	-13%	-$5.81M	0.27%	90
2014 Q1	$47.4M	Buy	912,037 +249,000	+38%	+$13.2M	0.36%	61
2013 Q4	$35.2M	Sell	663,037 -34,090	-5%	-$1.74M	0.29%	73
2013 Q3	$32.3M	Buy	697,127 +145,837	+26%	+$6.4M	0.33%	69
2013 Q2	$24.6M	Buy	+551,290	New	+$23.9M	0.31%	76

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Euclid Advisors's BMY Position: Q3 2016 in Review

Euclid Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2016, closing a stake of 63,647 shares — an estimated $4.68M sold.

Euclid Advisors first reported a position in BMY in Q2 2013 and held it in 11 quarters. The position peaked at $47.4M in Q1 2014. 1,523 funds tracked by Wall St. Rank hold BMY as of Q3 2016.

Euclid Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2016 after selling out during the quarter.
Euclid Advisors sold 63,647 Bristol-Myers Squibb shares in Q3 2016, an estimated $4.68M.
Euclid Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 11 quarters.
Euclid Advisors's Bristol-Myers Squibb position peaked at $47.4M in Q1 2014.
1,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.